You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.
We use strictly necessary cookies to keep you signed in. With your permission we'd also like to use anonymous analytics to improve the product. See our Cookie Policy and Privacy Policy.
111 compounds across peptides, hormones, and small molecules. 52 have full evidence profiles with mechanism summaries, evidence grades, and peer-reviewed citations. Information is for educational purposes only.
Sort
Compound class
Type
Evidence Grade
WADA Status
WADA status is educational and may change. Athletes are responsible for their own compliance with sport regulations; DoseVault accepts no liability. See the WADA reference for sources and dates.
Showing 22 of 111 compounds (10 with full profiles)
Small-molecule NNMT inhibitor that boosts NAD+ and white-fat mobilization.
Adipotide is a ligand-directed peptidomimetic: a cyclic CKGGRAKDC motif binds prohibitin on the endothelial cells that line white-adipose-tissue blood vessels, and a fused proapoptotic D(KLAKLAK)2 sequence disrupts mitochondrial membranes once internalized.
Weekly GLP-1 agonist fused to albumin; discontinued GSK product (Tanzeum/Eperzan).
Modified HGH fragment 176-191 analog targeted at fat loss without GH side effects.
Cagrilintide is a long-acting synthetic amylin analog that acts as an agonist at amylin receptors (AMY1, AMY2, AMY3) and the calcitonin receptor.
Semaglutide activates GLP-1 receptors to reduce appetite, slow gastric emptying, and improve glucose-dependent insulin secretion, while cagrilintide activates amylin receptors to promote satiety and slow gastric emptying.
Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.
First-in-class GLP-1 mimetic derived from Gila monster venom; sold as Byetta/Bydureon.
HGH Fragment 176-191 is a modified form of the C-terminal region of human growth hormone, comprising amino acids 176-191.
Daily GLP-1 analog; FDA-approved for diabetes (Victoza) and obesity (Saxenda®).
Short-acting prandial GLP-1 agonist; sold as Adlyxin/Lyxumia by Sanofi.
GLP-1 / glucagon dual agonist (Innovent / Eli Lilly) submitted in China for obesity 2024.
First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.
Retatrutide (LY3437943) is a long-acting triple agonist developed by Eli Lilly that simultaneously activates GLP-1, GIP, and glucagon receptors.
Combines retatrutide's triple agonism at GLP-1, GIP, and glucagon receptors with cagrilintide's long-acting amylin receptor agonism.
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and obesity management (Wegovy).
Investigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.
Teduglutide is a recombinant analog of glucagon-like peptide-2 (GLP-2) with a Gly2 substitution that resists DPP-4 degradation, extending its activity relative to native GLP-2.
Tesamorelin is an FDA-approved synthetic analogue of GHRH indicated for HIV-associated lipodystrophy.
Triple monoamine reuptake inhibitor with strong weight-loss data; not FDA-approved.
Tesofensine paired with metoprolol (Tesomet) to control HR while preserving weight loss.
Tirzepatide is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and obesity (Zepbound).
